Ordering Recommendation

Acceptable initial diagnostic and predictive test for PTEN-related disorders.


Polymerase Chain Reaction/Sequencing




14-21 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation

Lavender (K2EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature


Unacceptable Conditions

Ambient: 1 week; Refrigerated: 1 month; Frozen: 6 months

Reference Interval
Interpretive Data

Background Information for PTEN-Related Disorders (PTEN) Sequencing:
Characteristics of PTEN hamartoma tumor syndrome (PHTS):
Clinical findings are highly variable and include Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syndrome (PS) and Proteus-like syndrome (PSL).
CS: Multiple hamartoma syndrome with increased risk for malignant and benign tumors of the breast, thyroid and endometrium. Other associated findings include macrocephaly and mucocutaneous lesions (facial trichilemmomas, palmoplantar keratoses and papillomatous papules).
BRRS: Characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, hemangiomas and pigmented macules of the glans penis.
PS: A progressive disorder demonstrating mosaic distribution of associated lesions. Findings include hamartomatous tissue overgrowth, hyperostoses, connective tissue and epidermal nevi, dysregulated adipose tissue, vascular malformations and other congenital malformations.
PSL: Describes individuals with significant features of PS who do not meet clinical diagnostic criteria for PS.
At least 1 in 200,000 for CS; PS is rare with approximately 120 reported cases; unknown for other PTEN-associated conditions. 
Autosomal dominant. All mutations causing PS and 50-90 percent causing CS are de novo.
99 percent by 30 years of age for CS.  
Pathogenic PTEN gene mutations.
Clinical Sensitivity:
80 percent for CS, 60 percent for BRRS, 50 percent for PSL and 20 percent for PS.
Bidirectional sequencing of the PTEN promoter, coding region and intron-exon boundaries.
Analytical Sensitivity and Specificity:
99 percent.
: Diagnostic errors can occur due to rare sequence variations. Some regulatory region mutations, deep intronic mutations, and large deletion/duplications will not be detected. This assay is not designed to detect somatic variants associated with malignancy. Interpretation of this test result may be impacted if the patient has had an allogeneic stem cell transplantation.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)

Hotline History
CPT Codes


Component Test Code* Component Chart Name LOINC
2002723 PTEN FGS Specimen
2002724 PTEN-Related Disorders Interpretation
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Bannayan-Riley-Ruvalcaba Syndrome
  • Cowden Syndrome
  • Proteus Syndrome
  • Proteus-Like Syndrome
  • PTEN Sequencing assay
PTEN-Related Disorders (PTEN) Sequencing